Literature DB >> 24126833

Disease activity is an important factor for indeterminate interferon-γ release assay results in children with inflammatory bowel disease.

Ondrej Hradsky1, Jan Ohem, Kristyna Zarubova, Katarina Mitrova, Marianna Durilova, Radana Kotalova, Jiri Nevoral, Ilona Zemanova, Pavel Dryak, Jiri Bronsky.   

Abstract

BACKGROUND: Interferon-γ release assay (IGRA) is widely used for screening of latent tuberculosis (TB) before and during biological therapy (BT). An indeterminate result of IGRA represents a limitation in the management of inflammatory bowel disease (IBD). Data on factors influencing IGRA results are scarce in children. The aim of the study was to identify factors influencing IGRA results in children with IBD.
METHODS: Seventy-two children with IBD (59 Crohn disease, 11 ulcerative colitis, 2 IBD-unclassified) indicated for BT were tested for TB infection (history, TB skin test, chest radiograph, IGRA; QuantiFERON-TB Gold in tube [QFT]) and consecutively retested using QFT in 1-year intervals.
RESULTS: We recorded 165 results of QFT (3% positive, 87% negative, and 10% indeterminate results). During follow-up we identified 4 conversions of negative QFT to positivity (3%) and 4 reversions (4%). Patients with indeterminate results of QFT had significantly lower actual weight-for-height z score (P = 0.022), higher platelet count (P = 0.00017), and lower levels of serum albumin (P = 0.015) compared with patients with positive or negative QFT. Indeterminate QFT was associated with corticosteroid treatment, BT, and disease activity, but not with treatment by immunomodulators. In a subanalysis of patients with Crohn disease alone, Pediatric Crohn's Disease Activity Index was identified as single independent risk factor for indeterminate results (P = 0.00037).
CONCLUSIONS: Although corticosteroid treatment is traditionally considered to be the main risk factor for indeterminate results of IGRA, the disease activity of IBD has even more profound effects on the results.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24126833     DOI: 10.1097/MPG.0000000000000205

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  8 in total

1.  IGRA testing in patients with immune-mediated inflammatory diseases: which factors influence the results?

Authors:  Juan González-Moreno; Mercedes García-Gasalla; Inés Losada-López; Carmen Cifuentes Luna; Isabel Mir Viladrich; Victoria Fernández-Baca; Araceli Serrano; Antonio Juan Mas; Joan Riera-Oliver; Antoni Payeras Cifre
Journal:  Rheumatol Int       Date:  2017-10-19       Impact factor: 2.631

2.  Beyond QuantiFERON-TB Results, the Added Value of a Weak Mitogen Response.

Authors:  Marine Jacquier; Christine Binquet; Catherine Manoha; Sylvain Audia; Anne-Laure Simonet-Lamm; Alice Casenaz; Amadou-Khalilou Sow; Lionel Piroth; Mathieu Blot
Journal:  Front Med (Lausanne)       Date:  2022-05-30

3.  Neutrophil-to-Lymphocyte Ratio Is Associated with Impaired Interferon-Gamma Release to Phytohemagglutinin.

Authors:  Kwang-Sook Woo; Byoung-Gwon Kim; Jae-Lim Choi; Bo-Ram Kim; Kyeong-Hee Kim
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

Review 4.  Position statement of the Spanish Society of Pediatric Rheumatology on infection screening, prophylaxis, and vaccination of pediatric patients with rheumatic diseases and immunosuppressive therapies: Part 1 (screening).

Authors:  Esmeralda Núñez Cuadros; Joan Calzada-Hernández; Daniel Clemente; Sara Guillén Martín; Laura Fernández Silveira; María José Lirola-Cruz; Alfredo Tagarro; Marisol Camacho Lovillo; Rosa María Alcobendas Rueda; Agustín López López; Miren Satrustegi Aritziturri; Cristina Calvo
Journal:  Eur J Pediatr       Date:  2022-03-08       Impact factor: 3.860

5.  A Hierarchical Ensemble Deep Learning Activity Recognition Approach with Wearable Sensors Based on Focal Loss.

Authors:  Ting Zhao; Haibao Chen; Yuchen Bai; Yuyan Zhao; Shenghui Zhao
Journal:  Int J Environ Res Public Health       Date:  2022-09-16       Impact factor: 4.614

6.  Tuberculosis in pediatric patients treated with anti-TNFα drugs: a cohort study.

Authors:  Joan Calzada-Hernández; Jordi Anton-López; Rosa Bou-Torrent; Estíbaliz Iglesias-Jiménez; Sílvia Ricart-Campos; Javier Martín de Carpi; Vicenç Torrente-Segarra; Judith Sánchez-Manubens; Clara Giménez-Roca; Librada Rozas-Quesada; Maria Teresa Juncosa-Morros; Clàudia Fortuny; Antoni Noguera-Julian
Journal:  Pediatr Rheumatol Online J       Date:  2015-12-03       Impact factor: 3.054

7.  Tuberculosis and TNF-α inhibitors in children: how to manage a fine balance.

Authors:  Sara Parigi; Amelia Licari; Sara Manti; Gian Luigi Marseglia; Maria Angela Tosca; Michele Miraglia Del Giudice; Carlo Caffarelli; Mauro Calvani; Alberto Martelli; Fabio Cardinale; Claudio Cravidi; Marzia Duse; Elena Chiappini
Journal:  Acta Biomed       Date:  2020-09-15

8.  Challenges in screening for latent tuberculosis in inflammatory bowel disease prior to biologic treatment: a UK cohort study.

Authors:  Aye Aye Thi; Aula Abbara; Sonia Bouri; Simon M Collin; Paul Wolfson; Leah Owen; Kevin G Buell; Laurence John; Ailsa L Hart
Journal:  Frontline Gastroenterol       Date:  2018-04-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.